HR Execs on the Move

Aquinox Pharmaceuticals

www.aqxpharma.com

 
Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. Aquinox`s lead drug candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. Aquinox has a broad intellectual property portfolio and pipeline of preclinical drug candidates that activate SHIP1.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.aqxpharma.com
  • Suite 450 – 887 Great Northern Way
    Vancouver, BC CAN V5T 4T5
  • Phone: 604.629.9223

Executives

Name Title Contact Details
Shelley McCloskey
Vice President of Human Resources and Administration Profile
Shelley McCloskey
Vice President of Human Resources and Administration Profile

Similar Companies

Kira Biotech

Kira Biotech is an emerging Australian biotechnology company developing novel immunomodulatory compounds for the treatment of immune system disorders.

Kymanox

Kymanox is a professional services organization with a focus on project delivery. Our team of experts provide guide you and your project.

Drugstore Pharmacy

Drugstore Pharmacy is a Calgary, AB-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

EGEN

EGEN is a Huntsville, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ImmunoGen

Targeting a better life for people with cancer is why we get up in the morning. It`s not enough to disrupt the progress of someone`s cancer; we want to keep cancer from disrupting someone`s life. That`s why everything we do is about developing the most precise, targeted cancer therapies. We believe this is the best way to get people back to their lives—back to living today, tomorrow, and beyond. Because for us, targeting a better now is the only thing that matters. ImmunoGen is a leader in developing antibody-drug conjugates (ADCs). Our lead product candidate, mirvetuximab soravtansine, is a first-in-class folate receptor alpha (FRα)-targeting ADC with multiple studies underway in ovarian cancer. Our second pivotal program, IMGN632, is a CD123-targeting ADC being studied as a monotherapy in BPDCN and in combination in AML. Our earlier-stage assets in development are IMGC936, an ADAM9-targeting ADC in co-development with MacroGenics, and IMGN151, our next generation anti-folate receptor alpha ADC.